Literature DB >> 6162444

[Animal experiments for intratumoral chemotherapy with bleomycin (author's transl)].

J Bier, H Bier, B Lathan, T Siegel, S Ohanian.   

Abstract

The intense clinical interest in bleomycin as an anti-tumour agent has led to different methods of administration in an attempt to administer sufficiently high concentrations of the drug to the tumor. Therefore, a study was designed to determine the distribution and the therapeutic effect of a bleomycin emulsion and aqueous bleomycin after different routes of application. The tissue distribution of radioactively labelled bleomycin emulsion and aqueous bleomycin was determined in tumor-free CF 1 and tumor-bearing (EL 4, L 1210) C 57 Bl 6 and DBA 2 mice after local (s.c., i.t.) and systemic (i.v.) injection. The distribution studies for aqueous 57Co-bleomycin showed increased activity in the injection sites and the lymph nodes draining the injection sites after s.c. and i.t. injection compared to i.v. administration of the drug. In comparison to the aqueous local administration, the application of 57Co-bleomycin emulsion resulted in a disproportional increase of the 57Co-bleomycin concentration at the injection sites and in the draining lymph nodes. To prove the therapeutic relevance of the bleomycin tissue distribution tumor-bearing (line 10) strain 2 guinea pigs were treated with different modes of bleomycin. Animals with already lymphogenously metastasized tumors have been cured by means of low i.t. doses of the bleomycin emulsion. Guinea pigs treated with i.t. administration of aqueous bleomycin need, compared to the bleomycin emulsion, five times higher doses for tumor-free survival. Intravenously treated animals died either because of progressive tumor growth or because of toxic bleomycin effects. These findings made by animal experiments favor the i.t. treatment of head and neck carcinomas with a bleomycin emulsion.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6162444     DOI: 10.1007/BF00453748

Source DB:  PubMed          Journal:  Arch Otorhinolaryngol        ISSN: 0302-9530


  8 in total

1.  Intra-arterial bleomycin therapy in inoperable squamous cell carcinomas.

Authors:  M C Huntington; R W DuPriest; W S Fletcher
Journal:  Cancer       Date:  1973-01       Impact factor: 6.860

2.  Increased concentration of anticancer agents in regional lymph nodes by fat emulsions, with special reference to chemotherapy of metastasis.

Authors:  T Takahashi; M Mizuno; Y Fujita; S Ueda; B Nishioka
Journal:  Gan       Date:  1973-08

3.  Pharmacokinetics of bleomycin in man. III. Bleomycin 57Co Vs bleomycin.

Authors:  D S Alberts; H S Chen; J M Woolfenden; T E Moon; S Y Chang; J N Hall; K J Himmelstein; J Gross; S E Salmon
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

4.  [Animal experiments for intra-arterial chemotherapy with bleomycin (author's transl)].

Authors:  J Bier; E Loer; J Franke; H Platz
Journal:  Arch Otorhinolaryngol       Date:  1980

5.  Intraneoplastic injection of methotrexate for experimental brain-tumor chemotherapy.

Authors:  C H Tator; W Wassenaar
Journal:  J Neurosurg       Date:  1977-02       Impact factor: 5.115

6.  Intracavitary bleomycin in the management of malignant effusions.

Authors:  W Paladine; T J Cunningham; R Sponzo; M Donavan; K Olson; J Horton
Journal:  Cancer       Date:  1976-11       Impact factor: 6.860

7.  Pharmacokinetic behaviour of bleomycin-cobalt-57 with special regard to intraarterial perfusion of the maxillo-facial region.

Authors:  K Bitter
Journal:  J Maxillofac Surg       Date:  1976-12

8.  On the access of blood-borne dyes to various tumour regions.

Authors:  R J GOLDACRE; B SYLVEN
Journal:  Br J Cancer       Date:  1962-06       Impact factor: 7.640

  8 in total
  1 in total

1.  Aqueous intralesional bleomycin sclerotherapy in lymphatic malformation: Our experience with children and adult.

Authors:  Ankur Bhatnagar; Vijai Datta Upadhyaya; Basant Kumar; Zafar Neyaz; Ajay Kushwaha
Journal:  Natl J Maxillofac Surg       Date:  2017 Jul-Dec
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.